Paraoxonase 1 and atherosclerosis-related diseases

Jelena Kotur-Stevuljević*, Jelena Vekić, Aleksandra Stefanović, Aleksandra Zeljković, Ana Ninić, Jasmina Ivanišević, Milica Miljković, Miron Sopić, Jelena Munjas, Marija Mihajlović, Slavica Spasić, Zorana Jelić-Ivanović, Vesna Spasojević-Kalimanovska

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

53 Citations (Scopus)


A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.

Original languageEnglish
Pages (from-to)193-205
Number of pages13
Issue number2
Publication statusPublished - 1 Mar 2020
Externally publishedYes


  • HDL dysfunction
  • atherosclerosis
  • cancer
  • cardiovascular disease
  • diabetes
  • paraoxonase 1
  • renal disease
  • stroke


Dive into the research topics of 'Paraoxonase 1 and atherosclerosis-related diseases'. Together they form a unique fingerprint.

Cite this